Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Operating Leases (2019 - 2025)

Plus Therapeutics (PSTV) has disclosed Operating Leases for 7 consecutive years, with $15000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 51.61% to $15000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15000.0 through Dec 2025, down 51.61% year-over-year, with the annual reading at $15000.0 for FY2025, 51.61% down from the prior year.
  • Operating Leases for Q4 2025 was $15000.0 at Plus Therapeutics, down from $31000.0 in the prior quarter.
  • The five-year high for Operating Leases was $530000.0 in Q2 2021, with the low at $15000.0 in Q4 2025.
  • Average Operating Leases over 5 years is $181312.5, with a median of $127000.0 recorded in 2023.
  • The sharpest move saw Operating Leases fell 7.52% in 2021, then crashed 66.1% in 2024.
  • Over 5 years, Operating Leases stood at $504000.0 in 2021, then plummeted by 72.02% to $141000.0 in 2022, then plummeted by 39.72% to $85000.0 in 2023, then tumbled by 63.53% to $31000.0 in 2024, then crashed by 51.61% to $15000.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $15000.0, $31000.0, and $40000.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.